Clinical and microbiological characteristics of bloodstream infections in hematological cancer patients

Introduction. Bloodstream infections (BSI) are life-threatening illness for immunocompromised patients with hematological malignancies.
The aim of the study was to compare epidemiology, causative pathogens and outcome of hospital-acquired BSI and clarifying the role of herpes group of viruses in their development.
Materials and methods. During the period 1991–2013 438 bacterial strains obtained from 360 patients (pts) with hematological malignancies wеre studied. All blood cultures were incubated in the continuous monitoring system for 7 days before discard. The real-time PCR was used for human herpesviruses DNA detection: Herpes simplex viruses types 1 and 2 (HSV 1, 2), Cytomegalovirus (CMV), Epstein–Barr virus
(EBV) and Herpesvirus 6 (HHV-6). In this study 64 hematological cancer patients with infectious complications who fulfilled criteria of systemic inflammatory response syndrome with positive peripheral blood cultures were investigated. All pts received empirical anti-infectious therapy with subsequent correction based on the bacteriological, virological and mycological analyses.
Results and discussion. A total Gram-positive (G+) accounted for 69.2 % of BSI, Gram-negative (G–) for 30.8 %. Among G+ BSI Coagulase Negative Staphylococci and Staphylococcus aureus were the most frequent pathogens (58.8 %), among G– BSI Escherichia coli (13.0 %) was predominant. It is shown that the development of bacteremia were significantly more frequently occurs in the case of cytomegalovirus
and the Epstein–Barr virus detection.
Conclusion. Further epidemiological surveillance is warranted in order emerging resistant strains and related mortality. Reactivation of CMV and EBV is significantly associated with higher incidence of bacterial BSI.

infectious complications, sepsis, bacteremia, hemoblastosis

1. Щетинкина Е. Е., Бурылев В. В., Кайтанджан Е. И. и др. Этиология бактериемий и сепсиса у больных гемобластозами. Биомедицинский журнал Medline.ru 2014;15(41):511–8. [Shchetinkina E. E., Burylev V. V., Kaytandzhan E. I. et al. The etiology of bacteremia and sepsis in patients with hematological malignancies. Biomeditsinskiy zhurnal Medline.ru =Biomedical Journal Medline.ru 2014;15(41):511–518. (In Russ.)].

2. Кайтанджан Е. И., Волкова С. Д., Бурылев В. В. и др. Герпесвирусные инфекции у иммуносупрессивных больных и инфекционная безопасность гемотрансфузий. Вестник гематологии 2012; VIII(1):4–10. [Kaytandzhan E. I., Volkova S. D., Burylev V. V. et al. Herpesvirus infections in immunocompromised patients, and infectious safety of blood transfusions. Vestnik gematologii = Bulletin of Hematology 2012; VII(1):4–10. (In Russ.)].

3. Dellinger R. P., Levy M. M., Rhodes A. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39(2):165–228. DOI: 10.1007/s00134-012-2769-8.

4. Сепсис: классификация, клиникодиагностическая концепция и лечение. Прак тическое руководство. Под ред. В. С. Савельева, Б. Р. Гельфанда. 3-е изд. М.: МИА, 2013. 360 с. [Sepsis: classification, clinical and diagnostic concept and treatment. Practical Guide. Ed. by: V.S. Savel’ev, B. R. Gelfand 3rd edition. Moscow: MIA, 2013. 360 p. (In Russ.)].

5. Об унификации микробиологических (бактериологических) методов исследования, применяемых в клинико-диагностических лабораториях лечебно-профилактических учреждений. Приказ МЗ СССР № 535 от 22 апреля 1985 г. [Unification of microbiological (bacteriological) methods used in clinical diagnostic laboratories of health care institutions. The Order № 535 of Ministry of Health of the USSR, April 22, 1985. (In Russ.)].

6. Поляк М. С. Определение чувствительности микроорганизмов к противомикробным препаратам «методом дисков». СПб., 1997. 20 с. [Polyak M. S. Determination of microorganisms sensitivity to antimicrobial drugs by “disk test”. St.-Petersburg, 1997. 20 p. (In Russ.)].

7. Baker C. N., Stocker S. A., Culver D. H. et al. Comparison of E-test to agar dilution broth microdilution and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991;29:533–8. PMID: 2037671.

8. Стижак Н. П., Кайтанджан Е. И. Пейзаж микромицетов, выделенных из биоматериалов от больных гематологических клиник РосНИИГТ в период 2009–2011 гг. Вестник гематологии 2012;VIII(1):84. [Stizhak N. P., Kaytandzhan E. I. Мicromycetes isolated from biological materials from patients in RosNIIGT hematological clinics during 2009–2011. Vestnik gematologii = Bulletin of Hematology 2012;VIII(1):84. (In Russ.)].

9. Бессмельцев С. С., Абдулкадыров К. М. Множественная миелома: руководство для врачей. М.: МК, 2016. 504 с. [Bessmel’tsev S. S., Abdulkadyrov K. M. Multiple myeloma: Physi cians Guide. Moscow: MK, 2016. 504 p. (In Russ.)].

10. Meckes D. G., Shaira K. H., Marquitza A. R. et al. Human tumor virus utilizes exosomes for intercellular ommunication. Proc Natl Acad Sci USA 2010;107(47):20370–5. DOI: 10.1073/pnas.1014194107.

11. Henny F. C., Mulder C. J., Lampe A.S., van der Meer J.W. et al. Branhamella catarrhalis septicaemia in a granulocytopenic patient. Infection 1984;12(3):208–9. PMID: 6590467.

12. Saito H., Anaissie E. J., Khardori N. et al. Branhamella catarrhalis septicemia in patients with leukemia. Cancer 1988;61(11):2315–7. PMID: 3130177.

13. Sirwar S. B., Indupalli A. S., Pal R. et al. Moraxella catarrhalis: An emerging pathogen in bronchopulmonary infections. Ann Trop Med Publ Health 2013;6(1):76–9. DOI: 10.4103/1755-6783.115208.

14. Leszczyсska K., Jakoniuk P., Sacha P. T. et al. Susceptibility of Branhamella catarrhalis to antibiotics. Med Dosw Mikrobiol 2004;56:231–7. PMID: 15773499.

15. O’Grady N. P., Aleksander M., Burns L. A. et al. Healthcare Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2011;39 (4 Suppl 1):1–34. DOI: 10.1016/j ajic.2011.01.003.

16. Bender J.W., Hughes W. T. Fatal Staphylococcus epidermidis sepsis following bone marrow transplantation. Johns Hopkins Med J 1980;146:12–5. PMID: 6986499.

17. Wade J. C., Schimpff S. C., Newman K. A. et al. Staphylococcus epidermidis: an increasing cause of infection in patients with ranulocytopenia. Ann Intern Med 1982;97:503–8. PMID: 7125409.

18. Fuller A. K., Uglik K. M., William J. Savage W. J. et al. Bacterial Culture Reduces but Does Not Eliminate the Risk of Septic Transfusion Reactions to Single Donor. Transfusion 2009;49(12):2588–93. DOI: 10.1111/j.1537-2995.2009.02348.x.

19. Багирова Н. С. Таксономическая структура и резистентность к антибиотикам возбудителей инфекций кровотока у онкогематологических больных. Клиническая онкогематология 2015;8(2):191–200. [Bagirova N. S. Taxonomic structure and antibiotic resistance of blood pathogens in patients with hematological malignancies. Klinicheskaya onkogematologiya = Clinical Oncohematology 2015;8(2):191–200. (In Russ.)].

20. Чеботкевич В. Н., Бурылев В. В., Кайтанджан Е. И. и др. Этиологические и клинические особенности инфекционных осложнений при лейкозах. Онкогематология 2010;4:14–9. [Chebotkevich V. N., Burylev V. V., Kaytandzhan E. I. et al. Etiological and clinical features of infection in leukemia. Onkogematologiya = Oncohematology 2010;4:14–9. (In Russ.)].

21. Климко Н. Н. Диагностика и лечение кандидемии и острого диссеминированного кандидоза. Cosilium Medicum 2003;6:342–6. [Klimko N. N. Diagnosis and treatment of candidemia and acute disseminated candidiasis. Cosilium Medicum 2003;6:342–6. (In Russ.)].

22. Климко Н. Н., Пестова Л. А., Колбин А. С. и др. Эффективность и безопасность применения каспофунгина при инвазивном аспергиллезе у гематологических больных. Клиническая микробиология и антимикробная химиотерапия 2007;9(2):153–61. [Klimko N. N., Pestova L. A., Kolbin A. S. et al. Efficacy and safety of caspofungin in hematological patients with invasive aspergillosis. Klinicheskaya mikrobiologiya i antimikrobnaya terapiya = Clinical Microbiology and Antimicrobial Therapy 2007;9(2):153–61. (In Russ.)].